MacMahon B, Newill VA. Birth characteristics of children dying of malignant neoplasms. JNCI 1962; 28: 231–44.
Iversen T. Leukaemia in infancy and childhood. A material of 570 Danish cases. Acta Paediatr Scand [Suppl] 1966; 167: 25–50.
Jackson EW, Norris FD, Klauber MR. Childhood leukemia in California-born twins. Cancer 1968; 23: 913–9.
Fasal E, Jackson EW, Klauber MR. Birth characteristics and leukemia in childhood. JNCI 1971; 47: 501–9.
Wertelecki W, Mantel N. Increased birthweight in leukemia. Pediatr Res 1973; 7: 132–8.
Hirayma T. Descriptive and analytical epidemiology of childhood malignancy in Japan. In: Kobayashi N, ed. Recent Advances in Management of Children With Cancer. Tokyo, Japan: The Children's Cancer Association of Japan, 1980: 27–43.
Daling JR, Starzyk P, Olshan AF, Weiss NS. Birthweight and the incidence of childhood cancer. JNCI 1984; 72: 1039–41.
Shaw G, Lavey R, Jackson R, Austin D. Association of childhood leukemia with maternal age, birth origin, and paternal occupation. Am J Epidemiol 1984; 119: 788–95.
Eisenberg DE, Sorahan T. Birthweight and childhood cancer deaths. JNCI 1987; 78: 1095–100.
Shu XO, Gao YT, Brinton LA, et al. A population-based case-control study of childhood leukemia in Shanghai. Cancer 1988; 62: 635–44.
Kaye SA, Robison LL, Smithson WA, Gunderson P, King FL, Neglia JP. Maternal reproductive history and birth characteristics in childhood acute lymphoblastic leukemia. Cancer 1991; 68: 1351–5.
Savitz DA, Ananth CV. Birth characteristics of childhood cancer cases, controls, and their siblings. Ped Hematol Oncol 1994; 11: 587–99.
Cnattingius S, Zack MM, Ekbom A, et al. Prenatal and neonatal risk factors for childhood lymphatic leukemia. JNCI 1995; 87: 908–14.
Cnattingius S, Zack MM, Ekbom A, et al. Prenatal and neonatal risk factors for childhood myeloid leukemia. Cancer Epidemiol Biom Prev 1995; 4: 441–5.
Ross JA, Potter JD, Shu XO, Reaman GH, Lampkin B, Robison LL. Evaluating the relationships among maternal reproductive history, birth weight, and risk of infant leukemia. A report from the Childrens Cancer Group. Ann Epidemiol (in press).
Yeazel MW, Ross JA, Buckley JD, Woods WG, Ruccione K, Robison LL. High birthweight and risk of specific childhood cancers: a report from the Children's Cancer Group. (Submitted).
Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995; 75: 2186–95.
Ross JA, Davies SM, Potter JD, Robison LL. The epidemiology of childhood leukemia with a focus on infants. Epidemiologic Rev 1994; 16: 243–72.
Leisenring WM, Breslow NE, Evans IE, Beckwith JB, Coppes MJ, Grundy P. Increased birthweights of National Wilms' Tumor Study patients suggest a growth factor excess. Cancer Res 1994; 54: 4680–3.
Weksberg R, Shen DR, Fei YL, Song QL, Squire J. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann Syndrome. Nat Genet 1993; 5: 143–50.
Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 1993; 362: 749–51.
Olshan AF. Wilms' tumor, overgrowth, and fetal growth factors. A hypothesis. Cancer Genet Cytogen 1986; 21: 303–7.
Insulin-like growth factors. In: Pimental E, ed. Handbook of Growth Factors. Vol II. Peptide Growth Factors. Boca Raton, FL (USA): CRC Press, Inc., 1994: 55–95.
Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994; 42: 140–4.
Bennett A, Wilson DM, Liu F, Nagashima R, Rosenfeld RG, Hintz RL. Levels of insulin-like growth factors I and II in human cord blood. J Clin Endocinol Metab 1983; 57: 609–12.
Gluckman PD, Johnson-Barrett JJ, Butler JH, Edgar BW, Gunn TR. Studies of insulin-like growth factor-I and-II by specific radioligand assays in umbilical cord blood. Clin Endocrin 1983; 19: 405–13.
Ashton IK, Zapf J, Einschenk I, MacKenzie IZ. Insulin-like growth factors (IGF) 1 and 2 in human foetal plasma and relationship to gestational age and foetal size during midpregnancy. Acta Endocrinologica 1985; 110: 558–63.
Samaan NA, Schultz PN, Johnston DA, Creasy RW, Gonik B. Growth hormone, somatomedin C, and nonsuppressible insulin-like activity levels compared in premature, small, average birth weight, and large infants. Am J Obstet Gynecol 1987; B; 157: 1524–8.
Lasarre C, Hardouin S, Daffos F, Forestier F, Frankenne F, Binoux M. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects with intrauterine growth retardation. Ped Res 1991; 29: 219–25.
Salardi S, Orsini LF, Cacciari F, Righetti F, Donati S, Mandini M. Growth hormone, insulin-like growth factor I, insulin and C-peptide during human fetal life: in-utero study. Clin Endocrinol 1991; 34: 187–90.
Wang HS, Lim J, English J, Irvine L, Chard T. The concentration of insulin-like growth factor-I and insulin-like growth factor-binding protein-1 in human umbilical cord serum at delivery: relation to fetal weight. J Endrocrinol 1991; 129: 459–64.
Delmis J, Drazancic A, Ivanisevic M, Suchanek E. Glucose, insulin, HGH, and IGF-1 levels in maternal serum, amniotic fluid and umbilical venous serum: a comparison between late normal pregnancy and pregnancies complicated with diabetes and fetal growth retardation. J Perinat Med 1992; 20: 47–56.
Kubota T, Kamada S, Taguchi M, Aso T. Determination of insulin-like growth factor-2 in feto-maternal circulation during human pregnancy. Acta Endocrinologica 1992; 127: 359–65.
Fant M, Salafia C, Baxter RC, et al. Circulating levels of IGFs and IGF binding proteins in human cord serum. Relationships to intrauterine growth. Regulatory Peptides 1993; 48: 29–39.
Verhaeghe J, Van Bree R, Van Herck EV, Laureys J, Bouillon R, Van Assch FA. C-peptide, insulin-like growth factors I and II, and insulin-like growth factor binding protein-1 in umbilical cord serum: correlations with birth weight. Am J Obstet Gynecol 1993; 169: 89–97.
Reece EA, Wiznitzer A, Le E, Homko CJ, Behram H, Spencer EM. The relation between human fetal growth and fetal blood levels of insulin-like growth factors I and II, their binding proteins, and receptors. Obstet Gynecol 1994; 84: 88–95.
Simmons D. Interrelation between umbilical cord serum sex hormones, sex hormone-binding globulin, insulin-like growth factor 1, and insulin in neonates from normal pregnancies and pregnancies complicated by diabetes. J Clin Endocrinol Metab 1995; 80: 2217–21.
Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73–82.
Perentesis JP, Kersey JH. Biologic therapy in leukemia. In: Henderson ES, Lister TA, Greaves MF, eds. Leukemia, 6th Ed. London, UK: WB Saunders, 1996.
Baier TG, Jenne EW, Blum W, Shonberg D, Hartmann KK. Influence of antibodies against IGF-1, insulin or their receptors on proliferation of human acute lymphoblastic leukemia cell lines. Leuk Res 1993; 16: 807–14.
Sanders M, Sorba S, Daniak N. Insulin-like growth factors stimulate erythropoiesis in serum-substituted umbilical cord blood cultures. Exper Hematol 1993; 21: 25–30.
Jardieu P, Clark R, Mortensen D, Dorshkind K. In vivo administration of insulin-like growth factor-1 stimulates primary B lymphopoiesis and enhances lymphocyte recovery after bone marrow transplantation. J Immunol 1994; 152: 4320–7.
Estrov Z, Meir R, Barak Y, Zaizov R, Zadik Z. Human growth hormone and IGF-1 enhances the proliferation of leukemic blasts. J Clin Oncol 1991; 9: 394–9.
Shimon I, Shpilberg O. The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 1995; 19: 233–40.
Knudson AG, Meadows AT, Nichols WW, Hill R. Chromosomal deletion and retinoblastoma. N Engl J Med 1976; 295: 1120–3.
Volgelstein V, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525–32.
Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85: 2528–36.
Nucifora G, Larson RH, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long term remission. Blood 1993; 82: 712–5.
Morris JA. A mutational theory of leukemogenesis. J Clin Pathol 1989; 42: 337–40.
Wasserman R, Galili N, Ito Y, Reichard BA, Shane S, Rovera G. Predominance of fetal type DJH joining in young children with B-precursor lymphoblastic leukemia as evidence for an in utero transforming event. J Exper Med 1992; 176: 1577–81.
Steenbergen EJ, Verhagen OJ, Van Leeuwen EF, et al. B-precursor acute lymphoblastic leukemia third complementarily determining regions predominantly represent an unbiased recombination repertoire: leukemic transformation frequently occurs in fetal life. Euro J Immunol 1994; 24: 900–8.
Ford AM, Ridge SA, Cabrera ME, et al. In utero rearrangements in the trithorax-related oncogene in infant leukemias. Nature 1993; 363: 358–60.
Mahmoud HH, Ridge SA, Behm FG, et al. Intrauterine monoclonal origin of neonatal concordant acute lymphoblastic leukemia in monozygotic twins. Med Ped Oncol 1995; 24: 77–81.
Greaves MJ, Chan LC. Is spontaneous mutation the major ‘cause’ of childhood acute lymphoblastic leukemia? Br J Hematol 1986; 64: 1–13.
Metcalf D, Rasko JEJ. Leukemic transformation of immortalized FDC-P1 engrafted in GM-CSF transgenic mice. Blood 1993; 7: 878–86.
Cannistra SA, Groshak P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myelogenous leukemia. Leukemia 1989; 3: 328–34.
Buchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colony stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age after relapse. Blood 1991; 78: 1190–7.
Ganser A, Volkers B, Greher J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes — a phase I/II trial. Blood 1989; 73: 31–7.
Herrmann F, Lindemann A, Klein H, Lubbert M, Shulz G, Mertelsmann R. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 1989; 31: 335–8.
Williams GT, Smith CA. Molecular regulation of apoptosis. genetic controls on cell death. Cell 1993; 74: 777–9.
Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539–42.
Pui CH, Frankel LS, Carroll AJ, et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23). A collaborative study of 40 cases. Blood 1991; 77: 440–7.
Neiman PE, Thomas SJ, Loring G. Induction of apoptosis during normal and neoplastic B-cell development in the bursa of Fabricus. Proc Natl Acad Sci USA 1991; 88: 5857–61.
Muta K, Krantz SB. Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as erythropoietin. J Cell Physiol 1993; 156: 264–71.
Reaman G, Zeltzer P, Bleyer WA, et al. Acute lymphoblastic leukemia in infants less than one year of age. A cumulative experience of the Childrens Cancer Study Group. Blood 1985; 3: 1513–21.
Department of Health and Human Services. Compilations of Data on Natality, Mortality, Marriage, Divorce, and Induced Terminations of Pregnancy. No 1. Hyattsville, MD (USA): DHHS, May 1989; DHHS Publication No. (PHS) 89-1951, Vital and Health Statistics Supplements to the Monthly Vital Statistics Report. Series 24.